Unique ID issued by UMIN | UMIN000039155 |
---|---|
Receipt number | R000044657 |
Scientific Title | Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study). |
Date of disclosure of the study information | 2020/01/21 |
Last modified on | 2021/10/07 14:59:30 |
Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).
Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).
Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).
Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).
Japan |
Castration-resistant prostate cancer
Urology |
Malignancy
NO
To observe the long-term outcomes of patients enrolled in the OCUU-CRPC study comparing first-line treatment for castration-resistant prostate cancer after bicalutamide-based CAB therapy.
Efficacy
overall survival (OS)
time to treatment failure of ENZA therapy (TTF-ENZA)
Observational
20 | years-old | <= |
Not applicable |
Male
Of the 103 patients who obtained consent in the OCUU-CRPC study and were assigned at each institution.
None
103
1st name | Taro |
Middle name | |
Last name | Iguchi |
Osaka City University Graduate School of Medicine
Department of Urology
545-8585
1-4-3 Asahimachi, Abeno-ku, Osaka, Japan
06-6645-3857
taro@msic.med.osaka-cu.ac.jp
1st name | Taro |
Middle name | |
Last name | Iguchi |
Osaka City University Graduate School of Medicine
Department of Urology
545-8585
1-4-3 Asahimachi, Abeno-ku, Osaka, Japan
06-6645-3857
taro@msic.med.osaka-cu.ac.jp
Department of Urology, Osaka City University Graduate School of Medicine
Department of Urology, Osaka City University Graduate School of Medicine
Self funding
Ethical Committee of Osaka City University Graduate School of Medicine
Abeno Medics 6F, 1-2-7 Asahimachi, Abeno-ku, Osaka, Japan
06-6645-3456
ethics@med.osaka-cu.ac.jp
NO
2020 | Year | 01 | Month | 21 | Day |
Unpublished
103
No longer recruiting
2018 | Year | 12 | Month | 01 | Day |
2019 | Year | 02 | Month | 21 | Day |
2019 | Year | 02 | Month | 21 | Day |
2020 | Year | 12 | Month | 31 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 06 | Month | 30 | Day |
2023 | Year | 03 | Month | 31 | Day |
Observation items, inspection items, methods, etc.
- Prostate cancer treatment drug name, drug use period
- Opioid use and duration
- Blood test data (PSA, ALP, LDH, other blood chemistry test data)
- Imaging results (CT, bone scintigraphy, MRI, PET)
2020 | Year | 01 | Month | 14 | Day |
2021 | Year | 10 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044657
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |